CMS Medication Adherence Measures: How They Shape Medicare Part D Plans

Table of Contents#

1. Understanding CMS Medication Adherence Measures
   • Core Definition and Purpose
   • Key Measure Sets for Chronic Conditions
2. How Adherence Measures Drive Part D Plan Performance
   • Star Ratings and Financial Incentives/Penalties
   • Mandatory Quality Improvement Initiatives
   • Formulary and Pharmacy Network Adjustments
3. Impacts on Medicare Part D Beneficiaries
   • Enhanced Adherence Support Services
   • Potential Changes to Drug Coverage Access
   • Improved Long-Term Health Outcomes
4. Challenges Faced by Part D Plans
   • Balancing Cost and Adherence Goals
   • Addressing Disparities in Adherence
   • Data Collection and Reporting Burdens
5. Future Trends in CMS Adherence Measures
   • Expansion to New Chronic Conditions
   • Integration of Digital Health Tools
   • Shift Toward Value-Based Care Models
6. Conclusion
7. References

---

1. Understanding CMS Medication Adherence Measures#

Core Definition and Purpose#

CMS medication adherence measures quantify the percentage of beneficiaries who take their prescribed medications consistently over a defined period. These measures are designed to:

• Reduce preventable healthcare costs associated with non-adherence
• Improve health outcomes for individuals with chronic conditions
• Hold Part D plans accountable for supporting beneficiary medication adherence

Measures are developed in collaboration with the Pharmacy Quality Alliance (PQA) and aligned with national clinical guidelines to ensure relevance and accuracy.

Key Measure Sets for Chronic Conditions#

CMS focuses on high-impact chronic conditions where adherence directly correlates with health outcomes. The most widely used measures include:

• Adherence to Oral Antidiabetic Medications: Tracks consistency in taking medications for type 2 diabetes, a condition affecting 28% of Medicare beneficiaries.
• Persistence on ACE Inhibitors/ARBs for Heart Failure: Measures whether beneficiaries continue taking these life-saving medications for at least 12 months after a heart failure diagnosis.
• Adherence to Statins for Lipid Management: Evaluates consistent use of statins to lower cholesterol and reduce cardiovascular risk.
• Adherence to Antihypertensive Medications: Monitors compliance with blood pressure medications to prevent stroke and kidney disease.

Each measure uses pharmacy claims data to calculate a proportion score (e.g., 80% adherence means the beneficiary took their medication for 80% of the covered period).

---

2. How Adherence Measures Drive Part D Plan Performance#

Star Ratings and Financial Incentives/Penalties#

Adherence measures are a critical component of the Medicare Part D Star Ratings system, which evaluates plan quality across 10 domains. Adherence contributes to the Clinical Effectiveness domain, making up 20-25% of a plan’s overall star rating.

• Bonuses: Plans with a 4-star or higher rating receive annual bonus payments from CMS, which can range from 1-5% of their total revenue. These bonuses incentivize plans to invest in adherence programs.
• Penalties: Plans with a rating below 3 stars face restrictions, including being excluded from enrolling new beneficiaries after three consecutive years of low ratings. They may also be required to submit corrective action plans to CMS.

Mandatory Quality Improvement Initiatives#

CMS requires Part D plans to implement targeted quality improvement strategies to boost adherence. Common initiatives include:

• Medication Therapy Management (MTM): Free, personalized consultations with pharmacists for beneficiaries with multiple chronic conditions, high drug costs, and complex medication regimens. MTM includes medication reviews, adherence counseling, and dosage adjustments.
• Adherence Reminders: Automated phone calls, text messages, or email alerts to remind beneficiaries to refill prescriptions.
• Home Delivery Services: Waiving shipping fees for mail-order prescriptions to reduce barriers to access for rural or homebound beneficiaries.

Formulary and Pharmacy Network Adjustments#

Part D plans may revise their formularies (lists of covered drugs) and pharmacy networks to align with adherence goals:

• Tiered Formularies: Placing generic or lower-cost adherence-friendly drugs in lower tiers to reduce out-of-pocket costs for beneficiaries.
• Preferred Pharmacy Networks: Partnering with pharmacies that offer adherence support services (e.g., pill packaging, in-person counseling) and offering lower copays for beneficiaries who use these pharmacies.

---

3. Impacts on Medicare Part D Beneficiaries#

Enhanced Adherence Support Services#

Beneficiaries in high-performing Part D plans gain access to free or low-cost tools to improve adherence, such as:

• Custom pill organizers and blister packs
• Multilingual counseling services for non-English speakers
• Telehealth appointments with pharmacists to address medication questions

Potential Changes to Drug Coverage Access#

While adherence measures aim to improve outcomes, they may lead to minor changes in coverage:

• Plans may restrict coverage for non-adherence-friendly drugs (e.g., short-acting medications that require frequent dosing) in favor of longer-acting alternatives.
• Beneficiaries who consistently fail to adhere to prescribed medications may be required to participate in adherence programs to maintain coverage for certain drugs.

Improved Long-Term Health Outcomes#

Studies show that beneficiaries in plans with strong adherence programs experience:

• 20-30% lower rates of hospitalizations for chronic conditions
• 15-25% reduction in emergency department visits
• Better control of blood glucose, blood pressure, and cholesterol levels

---

4. Challenges Faced by Part D Plans#

Balancing Cost and Adherence Goals#

Investing in adherence programs (e.g., MTM, home delivery) increases operational costs for plans. To offset these expenses, some plans may raise premiums or adjust copays, creating a tension between improving adherence and keeping coverage affordable for beneficiaries.

Addressing Disparities in Adherence#

Certain beneficiary groups face higher rates of non-adherence due to systemic barriers:

• Low-income beneficiaries: May struggle to afford copays, even with extra help from Medicare.
• Rural beneficiaries: Limited access to pharmacies or transportation can hinder refill access.
• Minority populations: Language barriers and cultural differences may reduce engagement with adherence programs.

Plans must develop targeted strategies (e.g., sliding-scale copays, mobile pharmacy clinics) to address these disparities, which requires additional resources and coordination.

Data Collection and Reporting Burdens#

CMS requires plans to submit detailed adherence data quarterly, which involves:

• Integrating pharmacy claims data across multiple providers
• Validating data accuracy to avoid penalties for reporting errors
• Investing in data analytics tools to identify at-risk beneficiaries

Smaller plans often lack the resources to manage these reporting requirements, putting them at a disadvantage compared to larger, more well-funded plans.

---

5. Future Trends in CMS Adherence Measures#

Expansion to New Chronic Conditions#

CMS is expected to expand adherence measures to include conditions like chronic obstructive pulmonary disease (COPD) and mental health disorders, where non-adherence is a major driver of healthcare costs.

Integration of Digital Health Tools#

Plans will increasingly adopt digital tools to track and support adherence, such as:

• Mobile apps that send refill reminders and track medication intake
• Wearable devices that monitor health metrics (e.g., blood pressure) and link to medication adherence data
• AI-powered chatbots that answer medication questions in real time

Shift Toward Value-Based Care Models#

CMS is moving toward value-based care, where Part D plans are reimbursed based on patient outcomes rather than the number of prescriptions filled. Adherence measures will play a central role in these models, with plans earning higher payments for improving beneficiary adherence and reducing preventable costs.

---

Conclusion#

CMS medication adherence measures are a powerful tool for improving healthcare outcomes and reducing costs for Medicare Part D. While they create challenges for plans—including balancing cost and quality goals and addressing disparities—they ultimately benefit beneficiaries by expanding access to support services and driving better chronic disease management. As CMS continues to evolve these measures, stakeholders can expect to see greater integration of digital tools and a shift toward value-based care, further aligning plan incentives with patient needs.

---

References#

1. Centers for Medicare & Medicaid Services. (2024). Medicare Part D Star Ratings. Retrieved from https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/QualityMeasures/Medicare-Advantage-and-Part-D-Star-Ratings
2. Pharmacy Quality Alliance. (2023). Medication Adherence Measures. Retrieved from https://www.pqaalliance.org/measures/medication-adherence
3. National Council on Aging. (2023). Medication Non-Adherence Among Older Adults. Retrieved from https://www.ncoa.org/article/medication-non-adherence-among-older-adults
4. Centers for Medicare & Medicaid Services. (2024). Medication Therapy Management (MTM). Retrieved from https://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovGenInfo/Medication-Therapy-Management-MTM